Colorectal Cancer

  • Dominique Delbeke
  • Ronald C. Walker


Colorectal cancer (CRC) is the third most common cause of malignancy in both men and women. The incidence rate has decreased over the last two decades partially due to an increase in screening. The American Cancer Society estimates that there are approximately 149,000 new cases of CRC per year and approximately 50,000 patients per year die from this disease in the USA, representing 10% of new cases and 8% of all cancer deaths. Approximately 70–80% of patients are treated with curative intent, mostly by surgery. Chemotherapy alone, or in combination with radiation (for rectal cancer), is given before or after surgery to most patients whose tumor has penetrated the bowel wall or spread to lymph nodes. The overall survival at 1 and 5 years is 82 and 64%, respectively. The 5-year survival is 90% for localized stage, 68% when there is regional spread, and 10% when there are distant metastases.


Hepatic Resection Hepatic Metastasis National Comprehensive Cancer Network Mucinous Adenocarcinoma Extrahepatic Metastasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    American Cancer Society. Cancer facts and figures, 2008. Atlanta, Georgia.Google Scholar
  2. 2.
    Smith RA, Cokkinides V, Eyre HJ. American Cancer Society Guidelines for the early detection of cancer, 2004. CA Cancer J Clin 2004;54:41–52.CrossRefPubMedGoogle Scholar
  3. 3.
    McFarland EG, Levin B, Lieberman DA, Pickhardt PJ, Johnson CD, Glick SN, Brooks D, Smith RA. Revised colorectal screening guidelines: Joint effort of the American Cancer Society, U.S. Multisociety Task Force on Colorectal Cancer, and American College of Radiology. Radiology 2008;248:717–720.CrossRefPubMedGoogle Scholar
  4. 4.
    Agress H, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: Histopathologic comparison. Radiology 2004;230: 417–422.CrossRefPubMedGoogle Scholar
  5. 5.
    Kamel EM, Thumshirn M, Truninger K, Schiesser M, Fried M, Padberg B, Schneiter D, Stoeckli SJ, von Schulthess GK, Stumpe KDM. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: Correlation with endoscopic and histopathological results. J Nucl Med 2004;45:1804–1810.PubMedGoogle Scholar
  6. 6.
    Gutman F, Alberini JL, Wartski M, Vilain D, Le Stanc E, Sarandi F, Corone C, Tainturier C, Pecking AP. Incidental colonic focal lesions detected by FDG PET/CT. Am J Roentgenol 2005;185:495–500.CrossRefGoogle Scholar
  7. 7.
    Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, Fischer D. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: Incidence, localization patterns, and clinical significance. J Nucl Med 2005;46:758–762.PubMedGoogle Scholar
  8. 8.
    Yun HR, Lee LJ, Park JH, Cho YK, Cho YB, Lee WY, Kim HC, Chun HK, Yun SH. Local recurrence after curative resection in patients with colon and rectal cancers. Int J Colorectal Dis 2008;23:1081–1087.CrossRefPubMedGoogle Scholar
  9. 9.
    Helling TS, Blondeau B. Anatomic segmental resection compared to major hepatectomy in the treatment of liver neoplasms. HPB (Oxford) 2005;7:222–225.Google Scholar
  10. 10.
    Hughes KS, Simon R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, Maclean BJ, Foster JH, Daly JM, Fitzherbert D et al. Resection of liver for colorectal carcinoma metastases: A multi-institutional study of indications for resection. Surgery 1988;103:278–288.Google Scholar
  11. 11.
    Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, Gambhir SS. A meta-analysis of the literature for whole-body FDG PET detection of colorectal cancer. J Nucl Med 2000;41: 1177–1189.PubMedGoogle Scholar
  12. 12.
    Gambhir SS, Czernin J, Schimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated review of the literature. J Nucl Med 2001;42 (suppl):9S–12S.Google Scholar
  13. 13.
    Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, Birnbaum EH, Fleshman JW,  Kodner IJ, Read TE. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000;43:759–767; discussion 767–770.CrossRefPubMedGoogle Scholar
  14. 14.
    Berger KL, Nicholson SA, Dehadashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: Correlation of FDG uptake with histopathologic features. Am J Roentgenol 2000;174:1005–1008.Google Scholar
  15. 15.
    Yang YY, Fleshman JW, Strasberg SM. Detection and management of extrahepatic colorectal cancer in patients with resectable liver metastases. J Gastrointest Surg 2007;11:929–944.CrossRefPubMedGoogle Scholar
  16. 16.
    Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, Altman H, Keidar Z, Israel O. Clinical performance of PET/CT in the evaluation of cancer: Additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200–1209.PubMedGoogle Scholar
  17. 17.
    Roman CD, Martin WH, Delbeke D. Incremental value of fusion imaging with integrated PET-CT in oncology. Clin Nucl Med 2005;30:470–477.CrossRefPubMedGoogle Scholar
  18. 18.
    Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of FDG PET and PET-CT imaging in colorectal carcinoma. J Nucl Med 2003;44:1797–1803.PubMedGoogle Scholar
  19. 19.
    Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien P-A. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027–1034.CrossRefPubMedGoogle Scholar
  20. 20.
    Soyka JD, Veit-Haibach P, Strobel K, Breitenstein S, Tschopp A, Mende KA, Perez Lago M, Hany TF. Staging pathways in recurrent colorectal carcinoma: Is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice? J Nucl Med 2008;49:354–361.CrossRefPubMedGoogle Scholar
  21. 21.
    Tateishi U, Maeda T, Morimoto T, Miyake M, Arai Y, Kim EE. Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging 2007;34:1627–1634.CrossRefPubMedGoogle Scholar
  22. 23.
    Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, Corstens FHM, Oyen WJG. Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study. J Clin Oncol 2002;20:388–395.CrossRefPubMedGoogle Scholar
  23. 24.
    Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005;15;104:2658–2670.Google Scholar
  24. 25.
    Scott AM, Gunawardana DH, Kelley B, Stuckey JG, Byrne AJ, Ramshaw JE, Fulham MJ. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: Results of a multicenter prospective study. J Nucl Med 2008;49:1451–1457.CrossRefPubMedGoogle Scholar
  25. 26.
    Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study. Ann Surg 2001;233:320–321.CrossRefGoogle Scholar
  26. 27.
    Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240:438–447; discussion 447–450.CrossRefPubMedGoogle Scholar
  27. 28.
    Wiering B, Krabbe PF, Dekker HM, Oyen WJ, Ruers TJ. The role of FDG-PET in the selection of patients with colorectal liver metastases. Ann Surg Oncol 2007;14:771–779.CrossRefPubMedGoogle Scholar
  28. 29.
    Gambhir SS, Valk P, Shepherd J, Hoh C, Allen M, Phelps ME. Cost effective analysis modeling of the role of FDG-PET in the management of patients with recurrent colorectal cancer. J Nucl Med 1997;38:90P.Google Scholar
  29. 30.
    Park KC, Schwimmer J, Sheperd JE, Phelps ME, Czernin JR, Schiepers C, Gambhir SS. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg 2001;233:310–319.CrossRefPubMedGoogle Scholar
  30. 31.
    Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 2005;10:250–261.CrossRefPubMedGoogle Scholar
  31. 32.
    Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, Pratt B, Husband J, Flower M, Ott R. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14:700–708.PubMedGoogle Scholar
  32. 33.
    Akhurst T, Kates TJ, Mazumdar M, Yeung H, Riedel ER, Burt BM, Blumgart L, Jarnagin W, Larson SM, Fong Y. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005;23:8713–8716.CrossRefPubMedGoogle Scholar
  33. 34.
    Takahashi S, Kuroki Y, Nasu K, Nawano S, Konishi M, Nakagohri T, Gotohda N, Saito N, Kinoshita T. Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy. Anticancer Res 2006;26:4705–4711.PubMedGoogle Scholar
  34. 35.
    Carnaghi C, Tronconi MC, Rimassa L, Tondulli L, Zuradelli M, Rodari M, Doci R, Luttmann F, Torzilli G, Rubello D, Al-Nahhas A, Santoro A, Chiti A. Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy. Nucl Med Rev Cent East Eur 2007;10:12–15.PubMedGoogle Scholar
  35. 36.
    Lubezky N, Metser U, Geva R, Nakache R, Shmueli E, Klausner JM, Even-Sapir E, Figer A, Ben-Haim M. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: Comparison with operative and pathological findings. J Gastrointest Surg 2007;11:472–478.CrossRefPubMedGoogle Scholar
  36. 37.
    Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007;11:1112–1119.CrossRefPubMedGoogle Scholar
  37. 38.
    Anderson C, Koshy M, Staley C, Esiashvili N, Ghavidel S, Fowler Z, Fox T, Esteves F, Landry J, Godette K. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys 2007;69:155–162.CrossRefPubMedGoogle Scholar
  38. 39.
    Kahn H, Alexander A, Ratinic J, Nagle D, Fry R. Preoperative staging of irradiated rectal cancers using digital rectal examination, computed tomography, endorectal ultrasound, and magnetic resonance imaging does not accurately predict T0, N0 pathology. Dis Colon Rectum 1997;40:140–144.CrossRefPubMedGoogle Scholar
  39. 40.
    Moore HG, Akhurst T, Larson SM, Minsky BD, Mazumdar M, Guillem JG. A case controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg 2003;197:22–28.CrossRefPubMedGoogle Scholar
  40. 41.
    Guillem J, Calle J, Akhurst T, Tickoo S, Ruo L,  Minsky BD,  Gollub MJ,  Klimstra DS, Mazumdar M,  Paty PB, Macapinlac H, Yeung H,  Saltz L,  Finn RD, Erdi Y, Humm J, Cohen AM, Larson S. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-Fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000;43:18–24.CrossRefPubMedGoogle Scholar
  41. 42.
    Guillem JG, Moore HG, Akhurst T, Klimstra D, Ruo L, Mazumdar M, Minsky B, Saltz L, Wong W, Larson S. Sequential preoperative fluorodeoxyglucoise-Positron emission tomography assessment of response to preoperative chemoradiation: A means for determining longterm outcomes of rectal cancer. J Am Coll Surg 2004;199:1–7.CrossRefPubMedGoogle Scholar
  42. 43.
    Lin M, Shon IH, Wilson R, D'Amours SK, Schlaphoff G, Lin P. Treatment response in liver metastases following 90Y SIR-spheres: An evaluation with PET. Hepatogastroenterology 2007;54:910–912.PubMedGoogle Scholar
  43. 44.
    Podoloff DA, Advani RH, Allred C, Benson AB 3rd, Brown E, Burstein HJ, Carlson RW, Coleman RE, Czuczman MS, Delbeke D, Edge SB, Ettinger DS, Grannis FW Jr, Hillner BE, Hoffman JM, Kiel K, Komaki R, Larson SM, Mankoff DA, Rosenzweig KE, Skibber JM, Yahalom J, Yu JM, Zelenetz AD. NCCN task force report: Positron emission tomography (PET/Computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007;5(Suppl 1): S1–S22. www/ Google Scholar
  44. 45.
    Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VA, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF. Recommendations for the use of FDG (fluorine-18, (2-[18F]Fluoro-2-deoxy-D-glucose) positron emission tomography in oncology. J Nucl Med 2008;49:480–508.CrossRefPubMedGoogle Scholar
  45. 46.
    Van Kouwen MC, Nagengast FM, Jansen JB, Oyen WJ, Drenth JP. 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: A prospective study. J Clin Oncol 2005;23: 3713–3717.CrossRefPubMedGoogle Scholar
  46. 47.
    Friedland S, Soetikno R, Carlisle M, Taur A, Kaltenbach T, Segall G. 18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenomas and early stage colon cancer. Gastrointest Endosc 2005;61:305–400.Google Scholar
  47. 48.
    Kantorova I, Lipska L, Belohlavek O, Visokai V, Trubaĉ M, Schneiderová M. Routine 18F-FDG PET preoperative staging of colorectal cancer: Comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003;44:1784–1788.PubMedGoogle Scholar
  48. 49.
    Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MRimaging, PET) : A meta-analysis. Radiology 2002;224:748–756.CrossRefPubMedGoogle Scholar
  49. 50.
    Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, Stoker J. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis – meta-analysis. Radiology. 2005;237:123–131.CrossRefPubMedGoogle Scholar
  50. 51.
    Sahani DV, Kalva SP, Fischman AJ, Kadavigere R, Blake M, Hahn PF, Saini S. Detection of liver metastases from adenocarcinoma of the colon and pancreas: Comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol 2005;185:239–246.PubMedGoogle Scholar
  51. 52.
    Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, Greiss HB, Hofer GA. Whole-body PET imaging with F-18-fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg1999;134:503–511.CrossRefPubMedGoogle Scholar
  52. 53.
    Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, Marchal G, Filez L, Aerts R. Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging. Eur J Surg Oncol 1995;21:517–522.CrossRefPubMedGoogle Scholar
  53. 54.
    Flanagan FL, Dehdashti F, Ogunbiyi OA, Siegel BA. Utility of FDG PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319–323.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Radiology and Radiological SciencesVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations